Improved assessment of mass drug administration and health district management performance to eliminate lymphatic filariasis
by Carmen Maroto-Camino, Pilar Hernandez-Pastor, Naomi Awaca, Lebon Safari, Janet Hemingway, Marilia Massangaie, Donald Whitson, Caroline Jeffery, Joseph J. Valadez Lymphatic filariasis (LF) elimination as a public health problem requires the interruption of transmission by administration of preventive mass drug administration (MDA) to the eligible population living in endemic districts. Suboptimal MDA coverage leads to persistent parasite transmission with c onsequential infection, disease and disability, and the need for continuing MDA rounds, requiring considerable investment. Routine coverage reports must be verified in each MDA implementation unit (IU) due to incorrect denominators and numerators used to calculate coverage estimates with administrat ive data. IU are usually the health districts. Coverage is verified so IU teams can evaluate their outreach and take appropriate action to improve performance. Mozambique and the Democratic Republic of Congo (DRC) have conducted MDA campaigns for LF since 2009 and 2014, respectively. To verify distr ict reports and assess the declared achievement using administrative data of the minimum 80% coverage of eligible people (or 65% of the total population), both countries conducted rapid probability surveys using Lot Quality Assurance Sampling (LQAS)(n = 1102) in 2015 and 2016 in 58 IU in 49 district s. The surveys identified IU with suboptimal coverage, reasons for not residents did not take the medication, place where the medica...
Intellectual and Developmental Disabilities,Volume 57, Issue 6, Page 485-498, December 2019.
Intellectual and Developmental Disabilities,Volume 57, Issue 6, Page 499-511, December 2019.
Intellectual and Developmental Disabilities,Volume 57, Issue 6, Page 512-526, December 2019.
Intellectual and Developmental Disabilities,Volume 57, Issue 6, Page 527-544, December 2019.
Intellectual and Developmental Disabilities,Volume 57, Issue 6, Page 545-548, December 2019.
Intellectual and Developmental Disabilities,Volume 57, Issue 6, Page 549-550, December 2019.
Anti-Wolbachia therapy for onchocerciasis &lymphatic filariasis: Current perspectives. Indian J Med Res. 2019 Jun;149(6):706-714 Authors: Wan Sulaiman WA, Kamtchum-Tatuene J, Mohamed MH, Ramachandran V, Ching SM, Sazlly Lim SM, Hashim HZ, Inche Mat LN, Hoo FK, Basri H Abstract Onchocerciasis and lymphatic filariasis (LF) are human filarial diseases belonging to the group of neglected tropical diseases, leading to permanent and long-term disability in infected individuals in the endemic countries such as Africa and India. Microfilaricidal drugs such as ivermectin and albendazole have been used as t...
Publication date: 15 October 2017 Source:Veterinary Parasitology, Volume 245 Author(s): Ladawan Khowawisetsut, Patsharaporn T. Sarasombath, Suwich Thammapalo, Sumart Loymek, Therayot Korbarsa, Hathai Nochote, Achinya Phuakrod, Wej Choochote, Sirichit Wongkamchai Lymphatic filariasis (LF) is one of the neglected tropical diseases which causes permanent and long term disability worldwide. LF is caused by filarial nematode parasites, i.e. Wuchereria bancrofti, Brugia malayi, and B. timori. All available antifilarial drugs currently being used have shown a limited adulticidal activity. Discoveries of endosymbiont rickettsia-l...
ConclusionThis paper highlights the mode of action of the various antifilarial treatment strategies and role of host immune response.
Conclusions Available evidence strongly supports the effectiveness of hygiene-based lymphedema management in LF-endemic areas. Despite the aforementioned limitations, these findings highlight the potential to significantly reduce LF-associated morbidity and disability as well as the need to develop standardized approaches to MMDP in LF-endemic areas.